EurekaMag.com logo
+ Site Statistics
References:
47,893,527
Abstracts:
28,296,643
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Prospective study on the relationship between cervical neoplasia and herpes simplex virus type 2 herpes simplex virus type 2 antibody presence in sera taken at enrollment






International Journal of Cancer 33(1): 61-66

Prospective study on the relationship between cervical neoplasia and herpes simplex virus type 2 herpes simplex virus type 2 antibody presence in sera taken at enrollment

Sera obtained at enrollment in the study from patients suffering from moderate to severe dysplasia (cervical intraepithelial neoplasia grade II), carcinoma in situ (cervical intraepithelial neoplasia grade III) and invasive carcinoma, or developing any of these conditions in the course of the prospective study, and from control subjects, were examined for herpes simplex type-2 (HSV-2) antibody presence. The controls were matched with the patients by age, age at 1st intercourse, number of sexual partners, smoking habits and history of diathermoelectrocoagulation of the ectopic epithelium and transformation zone of cervix. Only those subjects were selected as controls who remained free of pathological colposcopical and cytological findings throughout the observation period, i.e., for at least 4 yr after their serum sample was obtained. The microneutralization test (MNT) and type-2-specific solid-phase radioimmunoassay (SPRIA) were used as serological tests. No difference in the prevalence of HSV-2 antibody between the patients and controls was revealed by either test. Various combinations of the results from the 2 tests also failed to show any difference between patients and controls. Moreover, no significant differences were observed in the prevalence of HSV-2 antibody between patients suffering from the various pathological conditions and those diagnosed at enrollment and later in the course of the study. These results do not provide any support for the hypothesis of the involvement of HSV-2 in cervical neoplasia.


Accession: 006206276



Related references

Vonka, V.; Kanka, J.; Hirsch, I.; Závadová, H.; Krcmár, M.; Suchánková, A.; Rezácová, D.; Broucek, J.; Press, M.; Domorázková, E., 1984: Prospective study on the relationship between cervical neoplasia and herpes simplex type-2 virus. II. Herpes simplex type-2 antibody presence in sera taken at enrollment. Sera obtained at enrollment in the study from patients suffering from moderate to sever dysplasia (cervical intraepithelial neoplasia grade II), carcinoma in situ (cervical intraepithelial neoplasia grade III) and invasive carcinoma, or developing...

Krcmar, M.; Suchankova, A.; Kanka, J.; Vonka, V., 1986: Prospective study on the relationship between cervical neoplasia and herpes simplex type 2 virus iii. presence of herpes simplex type 2 antibody in sera of subjects who developed cervical neoplasia later in the study. Paired sera taken from 63 subjects who developed cervical neoplasia in the course of a prospective study on this disease were examined for the presence of herpes simplex virus type 2 (HSV-2) antibody. The first serum was taken at enrollment into t...

Krcmár, M.; Suchánková, A.; Kanka, J.; Vonka, V., 1986: Prospective study on the relationship between cervical neoplasia and herpes simplex type 2 virus. III. Presence of herpes simplex type-2 antibody in sera of subjects who developed cervical neoplasia later in the study. Paired sera taken from 63 subjects who developed cervical neoplasia in the course of a prospective study on this disease were examined for the presence of herpes simplex virus type 2 (HSV-2) antibody. The first serum was taken at enrollment into t...

Cremer K.; Wohlenberg C.; Notkins A.L.; Mackett M.; Moss B., 1985: Vaccinia virus recombinant that expresses the herpes simplex virus type 1 glycoprotein d gene protects mice against lethal challenge by herpes simplex virus type 1 or herpes simplex type 2 and the establishment of a latent ganglionic infection by herpes simplex virus type 1. Lerner, R A , R M Chanock And F Brown (Ed ) Vaccines 85: Molecular And Chemical Basis Of Resistance to Parasitic, Bacterial, And Viral Diseases; Meeting, 1983 Xxi+407p Cold Spring Harbor Laboratory: Cold Spring Harbor, N Y , Usa Illus Paper 169-174

Vonka, V.; Kanka, J.; Jelinek, J.; Subrt, I.; Suchanek, A.; Havrankova, A.; Vachal, M.; Hirsch, I.; Domorazkova, E.; Et-Al, 1984: Prospective study on the relationship between cervical neoplasia and herpes simplex type 2 virus 1. epidemiological characteristics. To determine the risk associated with previous herpes simplex type 2 (HSV-2) infection and possibly other virus infections, a prospective study of cervical neoplasia in > 10,000 [randomly selected] women was performed. At enrollment colposcopy...

Vonka, V.; Kanka, J.; Jelínek, J.; Subrt, I.; Suchánek, A.; Havránková, A.; Váchal, M.; Hirsch, I.; Domorázková, E.; Závadová, H., 1984: Prospective study on the relationship between cervical neoplasia and herpes simplex type-2 virus. I. Epidemiological characteristics. To determine the risk associated with previous herpes simplex type-2 (HSV-2) infection and possibly other virus infections, a prospective study of cervical neoplasia in more than 10,000 women was performed in the 1975-1983 period. The subjects wer...

Lehtinen M.; Lehtinen T.; Koivisto V.; Paavonen J.; Leinikki P., 1985: Serum antibodies to the major herpes simplex virus type 2 specified dna binding protein in patients with an acute herpes simplex virus infection or cervical neoplasia. The major HSV-2-specified DNA-binding protein (ICSP 11/12) was purified from HSV-2-infected cells. ELISA (enzyme-linked immunosorbent assay) and immunoblotting techniques were used to study its antigenicity in HSV-infectd patients and patients wit...

Rosen A.; Darai G., 1985: Investigation of the virulence genes of herpes simplex virus type 2 by experimental infection in vivo with defined intertypic recombinants of a virulent herpes simplex virus type 2x an avirulent herpes simplex virus type. For determination of the gene loci for virulence and tropism of herpes simplex virus 2 (HSV-2) intertypic recombinants of HSV-1 strain HFEM and HSV-2 strain 3345 were screened for their pathogenicity in the tree shrew. HSV-1 strain HFEM is not pat...

Wilkie N.M.; Stow N.D.; Marsden H.S.; Preston V.; Cortini R.; Timbury M.C.; Subak Sharpe J.H., 1979: Physical mapping of herpes simplex virus coded functions and poly peptides by marker rescue and analysis of herpes simplex virus type 1 herpes simplex virus type 2 inter typic recombinants. De-The, G , W Henle And F Rapp (Ed ) Iarc (International Agency For Research on Cancer) Science Publications, No 24 Oncogenesis And Herpesviruses, Iii Part 1: Dna Of Herpesviruses, Viral Antigens, Cell-Virus Interaction; Proceedings Of The 3rd International Symposium, Cambridge, Mass , Usa, July 25-29, 1977 Lv+580p International Agency For Research on Cancer: Lyon, France Illus P11-32, 1978

Morse, L.S.; Pereira, L.; Roizman, B.; Schaffer, P.A., 1978: Anatomy of herpes simplex virus dna part 10 mapping of viral genes by analysis of poly peptides and functions specified by herpes simplex virus type 1 x herpes simplex virus type 2 recombinants. The provenance of the DNA sequences in 26 herpes simplex virus type 1 (HSV-1) .times. HSV-2 recombinants as determined from analyses of their DNA with at least 5 restriction endonucleases [HpaI, Bgl II, Xba I, EcoRI and Hsu I] was reported previou...